NCT03620669View on ClinicalTrials.gov

1st Line Durvalumab in PS 2 NSCLC Patients

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

December 4, 2018

Primary Completion Date

January 19, 2023

Study Completion Date

September 30, 2027

Conditions
NSCLC Stage IVNSCLC Stage IIIB
Interventions
DRUG

Durvalumab

Durvalumab 1500mg q4W until progression or unacceptable toxicity

Trial Locations (11)

1211

Hôpitaux Universitaires de Genève, Geneva

1708

Hopital Fribourgeois HFR, Fribourg

3010

Inselspital, Bern

3600

Spital STS AG, Thun

4031

Universitaetsspital Basel, Basel

5404

Kantonsspital Baden, Baden

6500

IOSI Ospedale Regionale di Bellinzona e Valli, Bellinzona

CH-5001

Kantonsspital Aarau, Aarau

CH-7000

Kantonsspital Graubuenden, Chur

CH-9007

Kantonsspital - St. Gallen, Sankt Gallen

CH-8401

Kantonsspital Winterthur, Winterthur

All Listed Sponsors
lead

Swiss Cancer Institute

OTHER

NCT03620669 - 1st Line Durvalumab in PS 2 NSCLC Patients | Biotech Hunter | Biotech Hunter